Enanta Pharmaceuticals (ENTA) Enterprise Value (2013 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Enterprise Value data on file, last reported at -$163.8 million in Q1 2026.

• Quarterly Enterprise Value rose 15.31% year-over-year to -$163.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$163.8 million (up 15.31% YoY) and the FY2025 annual result came in at -$188.9 million, down 399.1% from the prior year.
• Enterprise Value climbed to -$163.8 million in Q1 2026, from -$185.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$37.8 million in Q3 2024 to a low of -$386.6 million in Q2 2023.
• A 5-year average of -$210.5 million and a median of -$214.5 million in 2022 frame the typical range for Enterprise Value.
• The widest YoY moves for Enterprise Value: up 80.52% in 2025, down 399.1% in 2025.
• Tracing ENTA's Enterprise Value over 5 years: stood at -$214.5 million in 2022, then sank by 57.2% to -$337.2 million in 2023, then jumped by 35.73% to -$216.7 million in 2024, then gained by 14.23% to -$185.8 million in 2025, then rose by 11.88% to -$163.8 million in 2026.
• The last three Enterprise Value figures came in at -$163.8 million (Q1 2026), -$185.8 million (Q4 2025), and -$188.9 million (Q3 2025), per Business Quant data.